Cargando…
Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance
Cromoglycate (SCG) is widely used for allergy processes, and inflammatory states acting as a mast cell membrane stabilizer that inhibits the histamine and mediator release. Currently, SCG topical extemporaneous compounding formulations are prepared in hospitals and community pharmacies, as no indust...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302407/ https://www.ncbi.nlm.nih.gov/pubmed/37376057 http://dx.doi.org/10.3390/pharmaceutics15061609 |
_version_ | 1785065037585448960 |
---|---|
author | González-González, Olga Leal, Enrique Martín-Martínez, Mercedes Bautista, Liliana Ballesteros, Maria Paloma Torrado, Juan J. Serrano, Dolores R. |
author_facet | González-González, Olga Leal, Enrique Martín-Martínez, Mercedes Bautista, Liliana Ballesteros, Maria Paloma Torrado, Juan J. Serrano, Dolores R. |
author_sort | González-González, Olga |
collection | PubMed |
description | Cromoglycate (SCG) is widely used for allergy processes, and inflammatory states acting as a mast cell membrane stabilizer that inhibits the histamine and mediator release. Currently, SCG topical extemporaneous compounding formulations are prepared in hospitals and community pharmacies, as no industrial fabricated medicines are available in Spain. The stability of these formulations is unknown. Additionally, there are no clear guidelines on which concentration and vehicle are more suitable to enhance permeation across the skin. In this work, the stability of commonly prescribed topical SCG formulations in clinical practice was evaluated. Different vehicles commonly employed by pharmacists daily for formulating topical SCG were investigated (Eucerinum, Acofar Creamgel, and Beeler’s base) at different concentrations, ranging from 0.2 to 2%. The stability of topical extemporaneous compounded SCG formulations can be extended for up to three months at room temperature (25 °C). Creamgel 2% formulations significantly improved the topical permeation of SCG across the skin, being 4.5-fold higher than formulations prepared with Beeler’s base. The reason attributed to this performance can be related to the lower droplet size formed upon dilution in aqueous media combined with a lower viscosity, which facilitates its application and extensibility on the skin. The higher the SCG concentration in Creamgel formulations, the higher the permeability across both synthetic membranes and pig skin (p-value < 0.05). These preliminary results can be used as a guide to prompt a rational prescription of topical SCG formulations. |
format | Online Article Text |
id | pubmed-10302407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103024072023-06-29 Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance González-González, Olga Leal, Enrique Martín-Martínez, Mercedes Bautista, Liliana Ballesteros, Maria Paloma Torrado, Juan J. Serrano, Dolores R. Pharmaceutics Article Cromoglycate (SCG) is widely used for allergy processes, and inflammatory states acting as a mast cell membrane stabilizer that inhibits the histamine and mediator release. Currently, SCG topical extemporaneous compounding formulations are prepared in hospitals and community pharmacies, as no industrial fabricated medicines are available in Spain. The stability of these formulations is unknown. Additionally, there are no clear guidelines on which concentration and vehicle are more suitable to enhance permeation across the skin. In this work, the stability of commonly prescribed topical SCG formulations in clinical practice was evaluated. Different vehicles commonly employed by pharmacists daily for formulating topical SCG were investigated (Eucerinum, Acofar Creamgel, and Beeler’s base) at different concentrations, ranging from 0.2 to 2%. The stability of topical extemporaneous compounded SCG formulations can be extended for up to three months at room temperature (25 °C). Creamgel 2% formulations significantly improved the topical permeation of SCG across the skin, being 4.5-fold higher than formulations prepared with Beeler’s base. The reason attributed to this performance can be related to the lower droplet size formed upon dilution in aqueous media combined with a lower viscosity, which facilitates its application and extensibility on the skin. The higher the SCG concentration in Creamgel formulations, the higher the permeability across both synthetic membranes and pig skin (p-value < 0.05). These preliminary results can be used as a guide to prompt a rational prescription of topical SCG formulations. MDPI 2023-05-29 /pmc/articles/PMC10302407/ /pubmed/37376057 http://dx.doi.org/10.3390/pharmaceutics15061609 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article González-González, Olga Leal, Enrique Martín-Martínez, Mercedes Bautista, Liliana Ballesteros, Maria Paloma Torrado, Juan J. Serrano, Dolores R. Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance |
title | Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance |
title_full | Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance |
title_fullStr | Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance |
title_full_unstemmed | Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance |
title_short | Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance |
title_sort | guiding clinical prescription of topical extemporaneous formulations of sodium cromoglycate based on pharmaceutical performance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302407/ https://www.ncbi.nlm.nih.gov/pubmed/37376057 http://dx.doi.org/10.3390/pharmaceutics15061609 |
work_keys_str_mv | AT gonzalezgonzalezolga guidingclinicalprescriptionoftopicalextemporaneousformulationsofsodiumcromoglycatebasedonpharmaceuticalperformance AT lealenrique guidingclinicalprescriptionoftopicalextemporaneousformulationsofsodiumcromoglycatebasedonpharmaceuticalperformance AT martinmartinezmercedes guidingclinicalprescriptionoftopicalextemporaneousformulationsofsodiumcromoglycatebasedonpharmaceuticalperformance AT bautistaliliana guidingclinicalprescriptionoftopicalextemporaneousformulationsofsodiumcromoglycatebasedonpharmaceuticalperformance AT ballesterosmariapaloma guidingclinicalprescriptionoftopicalextemporaneousformulationsofsodiumcromoglycatebasedonpharmaceuticalperformance AT torradojuanj guidingclinicalprescriptionoftopicalextemporaneousformulationsofsodiumcromoglycatebasedonpharmaceuticalperformance AT serranodoloresr guidingclinicalprescriptionoftopicalextemporaneousformulationsofsodiumcromoglycatebasedonpharmaceuticalperformance |